JP2017507145A5 - - Google Patents

Download PDF

Info

Publication number
JP2017507145A5
JP2017507145A5 JP2016553402A JP2016553402A JP2017507145A5 JP 2017507145 A5 JP2017507145 A5 JP 2017507145A5 JP 2016553402 A JP2016553402 A JP 2016553402A JP 2016553402 A JP2016553402 A JP 2016553402A JP 2017507145 A5 JP2017507145 A5 JP 2017507145A5
Authority
JP
Japan
Prior art keywords
delivery system
substance delivery
matrix
polymeric material
anabolic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016553402A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017507145A (ja
JP6510547B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/053645 external-priority patent/WO2015124739A1/en
Publication of JP2017507145A publication Critical patent/JP2017507145A/ja
Publication of JP2017507145A5 publication Critical patent/JP2017507145A5/ja
Application granted granted Critical
Publication of JP6510547B2 publication Critical patent/JP6510547B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016553402A 2014-02-20 2015-02-20 Fgf−18を含むインプラント Active JP6510547B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14000598.4 2014-02-20
EP14000598 2014-02-20
PCT/EP2015/053645 WO2015124739A1 (en) 2014-02-20 2015-02-20 Implant comprising fgf-18

Publications (3)

Publication Number Publication Date
JP2017507145A JP2017507145A (ja) 2017-03-16
JP2017507145A5 true JP2017507145A5 (enExample) 2018-02-22
JP6510547B2 JP6510547B2 (ja) 2019-05-08

Family

ID=50151086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016553402A Active JP6510547B2 (ja) 2014-02-20 2015-02-20 Fgf−18を含むインプラント

Country Status (24)

Country Link
US (1) US10086112B2 (enExample)
EP (1) EP3107592B1 (enExample)
JP (1) JP6510547B2 (enExample)
KR (1) KR102421950B1 (enExample)
CN (1) CN106232154A (enExample)
AR (1) AR099556A1 (enExample)
AU (1) AU2015220785B2 (enExample)
BR (1) BR112016018681B1 (enExample)
CA (1) CA2938796C (enExample)
DK (1) DK3107592T3 (enExample)
ES (1) ES2698117T3 (enExample)
HR (1) HRP20181573T1 (enExample)
IL (1) IL247106B (enExample)
LT (1) LT3107592T (enExample)
MX (1) MX368946B (enExample)
NZ (1) NZ723177A (enExample)
PL (1) PL3107592T3 (enExample)
PT (1) PT3107592T (enExample)
RS (1) RS58138B1 (enExample)
RU (1) RU2700414C2 (enExample)
SG (1) SG11201606697YA (enExample)
SI (1) SI3107592T1 (enExample)
WO (1) WO2015124739A1 (enExample)
ZA (1) ZA201605667B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2658909C2 (ru) 2013-02-14 2018-06-26 НАНОПАРЕЙЛ, ЭлЭлСи Гибридные войлоки из нановолокон, полученных электропрядением
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen
WO2016120387A1 (en) 2015-01-29 2016-08-04 Ares Trading S.A. Immunoassays for high positively charged proteins
PL3688468T3 (pl) 2017-09-29 2022-07-18 Merck Patent Gmbh Biomarkery stanu zapalnego do przewidywania odpowiedzi na związek fgf-18
DK3687558T3 (da) 2017-09-29 2022-06-20 Merck Patent Gmbh Metaboliske biomarkører til forudsigelse af modtageligheden på fgf-18 forbindelse
IL281333B2 (en) 2018-09-10 2025-11-01 Merck Patent Gmbh A method for reducing risk in a clinical trial
CN117187255B (zh) * 2023-11-07 2024-01-30 北京大学第三医院(北京大学第三临床医学院) 编码FGF18或rhFGF18的mRNA及其在骨关节炎治疗中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220564T1 (de) * 1997-08-14 2002-08-15 Sulzer Innotec Ag Zusammensetzung und vorrichtung zur reparatur von knorpelgewebe in vivo bestehend aus nanokapseln mit osteoinduktiven und/oder chondroinduktiven faktoren
US6511958B1 (en) * 1997-08-14 2003-01-28 Sulzer Biologics, Inc. Compositions for regeneration and repair of cartilage lesions
KR100380119B1 (ko) * 2001-04-19 2003-04-11 한국항공우주연구원 이원화된 통신속도 적응형 베이스 밴드 스위칭 위상시프트 키잉 장치
EP1273365A1 (fr) * 2001-07-06 2003-01-08 Recherche Et Developpement Du Groupe Cockerill Sambre Outils rotatifs pour le perçage en ligne de produits profiles
US20040136970A1 (en) * 2002-10-07 2004-07-15 Ellsworth Jeff L. Methods for administering FGF18
US8852240B2 (en) * 2004-10-25 2014-10-07 Kieran Murphy, Llc Methods and compositions for fostering and preserving bone growth
PL1828239T3 (pl) * 2004-12-10 2012-01-31 Zymogenetics Inc Produkcja FGF18 w organizmach prokariotycznych
ZA200900426B (en) * 2006-08-25 2010-04-28 Ares Trading Sa Treatment of cartilage disorders with FGF-18
WO2010102266A1 (en) * 2009-03-05 2010-09-10 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of osteochondral defects
US8431399B2 (en) * 2010-03-02 2013-04-30 Taipei Medical University Method to restore cartilaginous phenotype of chondrocytes after cultured and expanded in vitro
WO2012094511A2 (en) * 2011-01-05 2012-07-12 Rhode Island Hospital Compositions and methods for the treatment of orthopedic disease or injury
JP5990720B2 (ja) * 2011-02-22 2016-09-14 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 骨再生及び/又は軟骨再生に使用するためのナノリザーバー技術
BR112016014717B1 (pt) * 2013-12-24 2020-12-01 Ares Trading S.A. sistema de gelificação de dois componentes, método para produção de um hidrogel homogêneo, e artigo de produção
AU2015220781B2 (en) 2014-02-20 2018-05-24 Merck Patent Gmbh FGF-18 in graft transplantation and tissue engineering procedures
EP3107559B1 (en) 2014-02-20 2018-07-11 Merck Patent GmbH Fgf-18 compound dosing regimen

Similar Documents

Publication Publication Date Title
JP2017507145A5 (enExample)
Haggerty et al. Biomaterials for revascularization and immunomodulation after spinal cord injury
RU2016137291A (ru) Имплантат, содержащий fgf-18
PE20170296A1 (es) Procedimiento para fabricar un producto de acetato de glatiramer
JP2014139220A5 (enExample)
MX384527B (es) Compuestos derivados de oxadiazolamina como inhibidores de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos
JP2017512194A5 (enExample)
MX376585B (es) Compuestos derivados de sulfamida de 1,3,4-oxadiazol como inhibidor de histona desacetilasa 6, y la composición farmacéutica que comprende los mismos.
JP2017507142A5 (enExample)
RU2016137292A (ru) Схема применения соединения fgf-18
JP2016517888A5 (enExample)
CN107115561B (zh) 一种3d打印支架材料及其制备方法和应用
JP2017522288A5 (enExample)
JP2011225596A5 (enExample)
JP2011528333A5 (enExample)
EA032951B1 (ru) Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
JP2017513809A5 (enExample)
JP2017105862A5 (enExample)
JP2017105859A5 (enExample)
HRP20180061T1 (hr) Indolkarbonitrili kao selektivni modulatori androgenskih receptora
NZ729628A (en) Methods for the treatment of peri-implantitis
JP2015515974A5 (enExample)
EP4474012A3 (en) Melatonin mini-tablets and method of manufacturing the same
JP2017525407A5 (enExample)
JP2020518588A5 (enExample)